局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展

血管瘤是婴幼儿最常见的良性肿瘤。根据部位、大小、范围、深度、分期、对患儿功能和心理的影响等因素不同,以局部外用和系统用药为主,辅以激光或局部药物注射。目前口服普萘洛尔是治疗浅表性血管瘤的一线药物,然而局部外用β受体阻滞剂更易于被患儿家长接受,其使用人数逐步增多。本文就近年来报道的有关β受体阻滞剂治疗婴幼儿血管瘤的研究现状进行综述,为婴幼儿血管瘤的临床治疗提供理论依据。

Progress in topical of application β-blockers in the treatment of infantile hemangioma

Hemangioma is the most common benign tumor in infants and young children. It is mainly treated by topical and systemic medication, supplemented by laser therapy, depending on the location, size, extent, depth, stage, functional and psychological impact on children. Oral propranolol is currently the first-line treatment for superficial hemangioma. However, topical β-blockers are more likely to be accepted by children's parents, and their use is gradually increasing. This article reviewed the research progress of β-blockers in the treatment of infantile hemangiomas in recent years, with the aim to provide a theoretical basis for the treatment of infantile hemangiomas.